Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease

E Peen, S Almer, G Bodemar, B-O Rydén, C Sjölin, K Teje, T Skogh

Abstract
Fifty two serum samples from patients with Crohn's disease, 24 from patients with ulcerative colitis, and 12 from patients with primary sclerosing cholangitis were analysed for the presence of anti-neutrophil cytoplasmic antibodies (ANCA) of IgG and IgA class by means of enzyme linked immunosorbent assays using lactoferrin, myeloperoxidase, and antigen extracted from azurophil granules, 'α antigen' (that is, an antigen preparation containing proteinase 3) as substrates. A high frequency of positive tests for IgG anti-lactoferrin antibodies was found in sera from patients with ulcerative colitis (50%) and primary sclerosing cholangitis (50%). In Crohn's disease only 4 of 52 (8%) sera had anti-lactoferrin antibodies — in all four instances the sera belonged to patients with disease involving the colon. All patients with sclerosing cholangitis and positive tests for anti-lactoferrin had ulcerative colitis. Low levels of IgG antibodies against myeloperoxidase or α antigen were also found occasionally in sera from patients with ulcerative colitis and primary sclerosing cholangitis. IgA antibodies directed against lactoferrin and α antigen (but not myeloperoxidase) were seen in all three conditions.

Since the description of anti-neutrophil cytoplasm antibodies (ANCA) in active Wegener's granulomatosis,1 the interest in anti-granulocyte antibodies has increased vastly. ANCA is now recognised as a family of autoantibodies directed against cytoplasmic antigens, mainly lysosomal enzymes, in polymorphonuclear neutrophil leukocytes (PMNL).2 In Wegener's granulomatosis, ANCA are typically directed against proteinase 3, a serine proteinase located in azurophilic granules of human PMNL.3 Anti-proteinase 3 antibodies may also occur in isolated, rapidly progressive glomerulonephritis and occasionally in systemic vasculitic conditions other than Wegener's granulomatosis.4 Antibodies directed against other lysosomal enzymes in PMNL azurophilic granules, for example myeloperoxidase and elastase, also occur in primary systemic vasculitides and rapidly progressive glomerulonephritis.5 6 After ethanol fixation of PMNL, proteinase 3 remains within the cytoplasmic granules, whereas myeloperoxidase and elastase become extracted and locate close to or on the cell nucleus.7 At indirect immunofluorescent microscopical determination of ANCA, anti-proteinase 3 antibodies produce a typical pancytoplasmatic granular staining pattern (C-ANCA), whereas anti-myeloperoxidase and anti-elastase antibodies give rise to a blury perinuclear staining pattern (P-ANCA) or staining of the PMNL nuclei (granulocyte specific anti-nuclear antibodies, GS-ANA).8 9 A detergent extract of isolated azurophil granules (α antigen) can be used for the detection of anti-proteinase 3 antibodies (C-ANCA) by means of enzyme linked immunosorbent assay (ELISA) but does not allow detection of anti-myeloperoxidase.10 11 Also, antibodies against lactoferrin, an iron binding protein residing in specific granules of PMNL,12 produce a P-ANCA pattern owing to perinuclear/nuclear localisation of lactoferrin after ethanol fixation.13 Apart from the antiformal GS-ANA staining pattern caused by antibodies directed against nucleophilic cytoplasmic antigens, it is possible that true GS-ANAs also exist.14

Apart from the occurrence in primary systemic vasculitides and rapidly progressive glomerulonephritis, P-ANCA/GS-ANA may be seen in other disease states, for example rheumatoid arthritis without signs of vasculitis,15 inflammatory bowel disease, and primary sclerosing cholangitis.16 17 Recent evidence favours the idea that inflammatory bowel disease may be caused by mesenteric vasculitis.16 18

In a preliminary study of 16 frozen sera from patients with Crohn's disease we found low levels of anti-α antigen antibodies, anti-myeloperoxidase antibodies, and anti-lactoferrin antibodies in some sera.19 The present study was done to extend these observations and to include sera from patients with ulcerative colitis and primary sclerosing cholangitis.

Patients and methods
CROHN'S DISEASE
Fifty two patients, 27 men aged 21–71 years (mean 48 years) and 25 women aged 17–55 years (mean 38 years) were enrolled in the study. The mean duration of the disease was 17 years (range 4–33 years). Eight patients had disease limited to the colon and/or rectum, 19 patients had disease in the small bowel alone, and 25 patients had disease manifestations in both small bowel and colon/rectum. Forty patients had been operated on, 14 of whom had been subjected to ileoceleal resection. Three patients had ileorectal anastomosis, and six patients had ileostomy after proctocolectomy.

ULCERATIVE COLITIS
Twenty four patients, 11 men aged 19–65 years...
Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease

(46 years), and 13 women aged 20–68 years (mean 42 years) participated in the study. Nineteen patients had left sided colitis and five patients had more extensive or total colitis. Fourteen of the patients had active disease – that is at least five loose stools with visible blood (all had visible inflammation at endoscopy) – and the remaining 10 patients were in clinical remission.

**PRIMARY SCLEROSING CHOLANGITIS**

Twelve patients, seven men aged 20–59 years (mean 46 years) and five women aged 35–63 years (mean 48 years), took part in the study. The diagnosis had been made by endoscopic retrograde cholangiography 3 years (range 1–6 years) before the study. Two patients had only intrahepatic cholangitis and 10 had both extra- and intrahepatic cholangitis. In four patients cirrhosis of the liver had been diagnosed at histopathological examination of liver biopsies. One patient had undergone liver transplantation 6 years earlier. Nine of the 12 patients had also suffered from ulcerative colitis for 8 years (range 0–21 years) and one had non-specific colitis. In the two remaining patients no accompanying disease had been diagnosed. None of the patients had Crohn’s disease.

One of the patients originally participating in the study had to be excluded as she proved to have suffered from acute *Campylobacter jejuni* colitis.

**ANTIGEN PREPARATIONS**

Azurophil granules were prepared from isolated normal peripheral granulocytes after low pressure homogenisation of the cells and centrifugation of the homogenate in a Percoll (Pharmacia Fine Chemicals, Uppsala, Sweden) gradient as described elsewhere. The granules were lysed with 0.01% (final concentration) Triton X-100 (Merck, Darmstadt, Germany). The extract thus achieved (α antigen) was diluted in carbonate-bicarbonate buffer pH 9.5 and used as substrate for ELISA.

Lyophilised preparations of myeloperoxidase (Calbiochem, La Jolla, CA, USA), human milk lactoferrin (Sigma Chemical Co, St Louis, MO, USA), and bovine milk lactoferrin (Sigma) were dissolved in carbonate-bicarbonate buffer (10 μg antigen/ml) and used for ELISA.

**ELISA**

High binding plastic microtitre plates (Nunc Immunoplate, Roskilde, Denmark) were coated with α antigen, myeloperoxidase, or human lactoferrin solutions by incubation at 4°C for 12 hours. After washing with buffer (phosphate buffered saline, PBS, 0.05% Tween 20), serum samples (diluted 1:10 in PBS-Tween) were applied for 30 minutes at room temperature. Normal human serum diluted 1:10 served as a blank. The microtitre plates were washed thoroughly with PBS-Tween and incubated for another 30 minutes with alkaline-phosphatase (ALP) conjugated rabbit anti-human γ chain or rabbit anti-human α chain antisera (Dako, Glostrup, Denmark) diluted 1:400 in PBS-Tween. After washing, the substrate buffer was applied and the optical density (OD) read at 405 nm when the positive reference samples had reached OD 1.0. OD values exceeding 2 SDs of the reference material from healthy blood donors (n=218 for IgG tests; n=211 for IgA tests) were considered positive. The IgG autoantibody analyses were performed on all sera from patients with Crohn’s disease (n=52), ulcerative colitis (n=24), and primary sclerosing cholangitis (n=12). IgA autoantibody tests were done on sera from 51 patients with Crohn’s disease, 11 ulcerative colitis sera, and 11 sera from patients with primary sclerosing cholangitis.

**Figure 1:** Diagram to illustrate the ELISA results of IgG autoantibody directed against α antigen, myeloperoxidase, and lactoferrin in sera from patients with Crohn’s disease (n=52), ulcerative colitis (n=24), and primary sclerosing cholangitis (n=12). The lower limit for positive ELISA (that is, +2 SD of the mean value of 218 normal reference sera) is indicated.
Figure 2: Sodium dodecyl sulphate polyacrylamide gels (SDS-PAGE) electrophoresis of the human milk lactoferrin preparation (lane 1) showed only material of molecular weight about 80 kD when stained with Comassie blue. Lane 2 shows molecular weight markers for comparison. Immunoblotting, using polyclonal rabbit anti-human leukocyte lactoferrin, showed slight reaction with antigens of lesser molecular weight, apart from the strong reaction with the 80 kD lactoferrin band (lane 3). Patients sera positive for IgG anti-human milk lactoferrin, as tested by ELISA, however, reacted only with lactoferrin.

IgG anti-bovine lactoferrin antibodies were measured essentially as described above, except that no negative or positive serum references were used. OD values were read after 30 minutes incubation with substrate buffer. Eleven positive and 10 negative sera in the test for IgG anti-human lactoferrin were selected for this analysis.

RABBIT ANTI-LACTOFERRIN ANTISERA
Serum containing polyclonal rabbit anti-human leukocyte lactoferrin was the kind gift of Dr Johan Richter, Department of Internal Medicine, University Hospital, Lund, Sweden. To produce anti-human milk lactoferrin antibodies, rabbits were immunised by subcutaneous injections of 2 mg human milk lactoferrin (that is, the same antigen as that used for the ELISA and western blot assays) together with Freund’s incomplete adjuvant (Sigma) on three occasions with 4 week intervals. The reason for not using Freund’s complete adjuvant was to avoid immunisation against hsp-65, because of its immunological cross reaction with human lactoferrin. Two weeks after the second booster dose, the animals were anaesthetised with barbiturate, and exsanguinised by heart puncture. Serum was pooled. Anti-lactoferrin activity of the serum was confirmed by agarose double radial immunodiffusion against human milk lactoferrin.

WESTERN BLOTTING
Lactoferrin (1 µg per lane) was electrophoresed in 5–20% sodium dodecyl sulphate polyacrylamide gels (SDS-PAGE) and transferred to polyvinylidene difluoride membranes (Millipore Continental Water Systems, Bedford, MA, USA). Blocking was done with 5% bovine serum albumin (Sigma) in PBS. Anti-lactoferrin positive patient sera (as judged by ELISA) were diluted 1:20 or 1:200 in PBS-Tween with 1% bovine serum albumin, and applied for 1 hour.

The rabbit anti-human leukocyte lactoferrin served as a reference. ALP conjugated anti-human IgG and anti-rabbit IgG (Dako) were used as secondary antibodies.

INDIRECT IMMUNOFLUORESCENCE (IIF) MICROSCOPY
To study the distribution of lactoferrin in ethanol fixed granulocytes cytocentrifuged onto microscope slides, the slides were incubated with rabbit anti-human milk lactoferrin in a moist chamber for 30 minutes. After washing with PBS and incubation for another 30 minutes with sheep fluorescin isothiocyanate (FITC) conjugated anti-rabbit Ig (Wellcome Diagnostics, Temple Hill, Dartford, UK), the slides were again washed with PBS, mounted with PBS-glycerin, and inspected under a fluorescence microscope with a mercury lamp (HBO 50) epillumination and filters for FITC activation/ emission.

STATISTICS
Differences in ELISA results between the control sera and the patient sera were evaluated by the χ² test, and divided into four groups: p=0.05 = not significant (NS); p<0.05 (*); p<0.01 (**); p<0.001 (***).

Results
The frequencies of IgG antibodies directed against α antigen, myeloperoxidase, and lactoferrin are shown in Figure 1. In Crohn's disease 4 of 52 sera had IgG anti-α antigen, which is not statistically different from the control group, although two of the sera had remarkably high antibody levels. In ulcerative colitis 4 of 24 of the sera contained IgG anti-α antigen antibodies (p<0.05), and in primary sclerosing cholangitis 4 of 12 sera (p<0.001) were positive.

IgG anti-myeloperoxidase antibodies occurred in 3 of 52 of the sera taken from patients with Crohn’s disease (not statistically different from
Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn’s disease

The lactoferrin. Fifty the sera; IgA anti-lactoferrin antibodies were found in 50% of the sera (p<0.001 in both instances). All of the anti-lactoferrin positive cholangitis sera belonged to patients suffering from concomitant ulcerative colitis – that is, 6 of 9 (67%) sera from patients with sclerosing cholangitis and concomitant ulcerative colitis contained IgG anti-lactoferrin antibodies. Two of the sera from patients with primary sclerosing cholangitis and one serum from a patient with ulcerative colitis were positive in all three ELISA tests. However, in all three instances the ELISA tests gave quite different OD values in the different assays, indicating true positive ELISA test results.

Positive anti-lactoferrin ELISA results were blocked by preincubation of the lactoferrin-coated microtitre plates with rabbit IgG anti-lactoferrin (not illustrated). The occurrence of IgG anti-lactoferrin was also confirmed by western blotting, revealing a single reaction band with an antigen of molecular weight about 80 000 and corresponding to rabbit anti-human leucocyte lactoferrin (Figure 2).

One patient originally included in the study had acute colitis and a high level of IgG anti-lactoferrin at the first sampling occasion, and a further raised anti-lactoferrin level in a later serum sample (not illustrated). This patient was, however, excluded from the study since her symptoms were explained by infection with Campylobacter jejuni.

Figure 3 illustrates the lack of correlation between levels of IgG anti-human lactoferrin and IgG anti-bovine lactoferrin as tested by ELISA with 10 sera positive in the anti-human lactoferrin and 12 sera negative in the same test.

Figure 4 shows the occurrence of IgA antibodies directed against α antigen, myeloperoxidase, and human lactoferrin.

Raised levels of IgA anti-α antigen were seen in 12 of 51 (24%) sera from Crohn’s disease (p<0.001), in 5 of 11 (45%) sera from patients with primary sclerosing cholangitis (p<0.001), but in only 2 of 21 (10%) sera from patients with ulcerative colitis (NS). The levels of IgA anti-myeloperoxidase did not differ from the control group in any of the disease states, whereas IgA anti-lactoferrin was significantly (p<0.05) more common in Crohn’s disease, although it was seen only in a minority of the patient sera (5 of 51 = 10%). IgA anti-lactoferrin was found in significantly (p<0.001) increased frequency also in ulcerative colitis (7 of 21 = 33%), but not in sclerosing cholangitis (1 of 11 = 9%).

The levels of IgA-ANCAs were not explained by the occurrence of agglutinating rheumatoid factors (not illustrated).

Figure 5 shows the frequency of positive IgG and/or IgA tests for either anti-α antigen, or anti-myeloperoxidase, or anti-lactoferrin in sera from blood donors, Crohn’s disease, ulcerative colitis, and primary sclerosing cholangitis. Taken together, positive IgG tests for one or more of the three granulocyte antigens were found in 11% (24 of 218) control sera, in 19% (10 of 52) of Crohn’s disease (NS), in 67% (16 of 24) of ulcerative colitis (p<0.001), and in 67% (8 of 12) of primary sclerosing cholangitis sera; IgA anti-granulocyte antibodies were found in 7% (15 of 211) of the controls, in 29% (15 of 51) of Crohn’s

![Figure 4: Results of the ELISA tests for IgA autoantibodies directed against α antigen, myeloperoxidase, and lactoferrin. Fifty one sera from patients with Crohn’s disease, 21 sera from patients with ulcerative colitis, and 11 sera from patients with primary sclerosing cholangitis were analysed. The cut of levels (that is, values exceeding 2 SD of the mean of a reference material of 211 normal sera) are indicated.](http://gut.bmj.com/ on October 13, 2017 - Published by group.bmj.com)
antibodies. The levels of IgG and IgA anti-granulocyte antibodies did not correlate to the total serum levels of IgG and IgA (not illustrated).

Figure 6 shows the GS-ANA/P-ANCA immunofluorescence pattern of cyto centrifuged ethanol-fixed human polymorphonuclear neutrophil granulocytes after staining with rabbit anti-human milk lactoferrin. This, taken together with the western blot analysis (Fig 2), shows that antibodies against human milk lactoferrin recognise human leukocyte lactoferrin and vice versa.

Discussion

In this study we report high frequencies of IgG anti-lactoferrin antibodies (corresponding to P-ANCA) in sera from patients with ulcerative colitis and primary sclerosing cholangitis. In Crohn’s disease, however, serum anti-lactoferrin antibodies of IgG were rarely detected, and then only in patients with colonic disease manifestations. IgA anti-lactoferrin antibodies were, however, found in some cases of both ulcerative colitis and Crohn’s disease.

Several different types of autoantibodies have been described in inflammatory bowel disease and primary sclerosing cholangitis. 

Although none of the autoantibodies have been proved to be of pathogenetic significance, it has been shown, both in Crohn’s disease and in ulcerative colitis, that IgG and complement can be present on the apical surface of enterocytes in vivo, possibly indicating a pathogenetic role for anti-epithelial/anti-brush border antibodies in inflammatory bowel disease. In this connection, and considering the high frequency of anti-lactoferrin antibodies found in the present study, it is interesting to note that lactoferrin has been reported to bind to intestinal brush border via a specific receptor. Antibodies of IgA class directed against Saccharomyces cerevisiae are common in Crohn’s disease but not in ulcerative colitis, and determination of such antibodies may be of diagnostic help. It is possible that many of the anti-microbial antibodies described in inflammatory bowel disease and other inflammatory disease states, may in fact be reflections of immunisation against microbial heat-shock proteins, which has been implied in the pathogenesis of several autoimmune disease states and which may induce anti-lactoferrin antibodies (see below).

Wakefield et al presented evidence that vasculitis and microthrombosis in mesenteric vessels can be important pathogenetic factors in inflammatory bowel disease. Furthermore, P-ANCA/GS-ANA, which occurs in several primary vasculitides, can frequently be demonstrated in inflammatory bowel disease and primary sclerosing cholangitis also. P-ANCA/GS-ANA is more common in ulcerative colitis than in Crohn’s disease, which is confirmed in the present study by the high frequency of IgG anti-lactoferrin antibodies in ulcerative colitis and primary sclerosing cholangitis but not in Crohn’s disease. In Crohn’s disease the frequency of IgG anti-α antigen and anti-myeloperoxidase antibodies did not differ.
statistically from the control group, although in a few instances the antibody levels were surprisingly high. In both ulcerative colitis and primary sclerosing cholangitis the frequency of positive IgG α/α-anti-myeloperoxidase tests differed statistically from the control group, but in general the levels were low and, considering the small number of patients with positive anti-α/α-anti-myeloperoxidase tests, the relevance of these results is uncertain. However, it is interesting that these types of ANCA were found at all, since they are considered to be reliable markers of primary systemic vasculitides and ANCA class have been reported in Hennoch-Schönlein purpura and IgA nephropathy, although these findings are sometimes explained by the presence of rheumatoid factor. The appearance of antibodies directed against α antigen in some cases of ulcerative colitis (IgG) and in Crohn’s disease (IgA) could possibly favour the hypothesis of primary vasculitis as a pathogenetic factor in these diseases. Lactoferrin is an iron binding protein that occurs abundantly not only in the specific granules of granulocytes, but also in tears, milk, and secretions at mucosal surfaces. Raised levels of circulating lactoferrin are seen during active inflammatory disease. It exerts anti-bacterial effects by depriving bacteria of iron required for growth, and it has anti-inflammatory properties — for example, by preventing complement activation through inhibition of classical C3 convertase. Lactoferrin can also prevent the formation of hydroxyl radicals by iron binding. Lactoferrin may thus be of great importance as a non-specific anti-phlogistic defence factor at the primary immunological barriers. It has been shown experimentally that binding of lactoferrin by anti-lactoferrin antibodies increases the amount and duration of hydroxyl radical formation by granulocytes. Hypothetically, anti-lactoferrin autoantibodies could, by counteracting the anti-inflammatory effects of lactoferrin, aggravate and prolong mucosal inflammation induced by several different mechanisms, and the antibodies may therefore have pathogenetic significance even though their occurrence does not seem to correlate with disease activity. Anti-lactoferrin antibodies may also have pathogenetic effects by activation of primed granulocytes infiltrating the gut mucosa or adhering to vessel walls, in analogy with the effects of other types of ANCA. In addition, mucosal lactoferrin/anti-lactoferrin complexes may stimulate intestinal goblet cell secretion, as do other immune complexes. On the other hand, the occurrence of anti-lactoferrin autoantibodies may, of course merely be an epiphenomenon without pathogenetic significance. The fact that the individual types of ANCA were found only in a minority (≤50%) of the sera tested is an argument in favour of this. On the other hand, consumption of circulating antibodies cannot be ruled out in the seronegative instances. The origin of anti-lactoferrin autoantibodies is unknown. Although bovine and human lactoferrin have molecular and antigenic similarities, immunisation of experimental animals with bovine lactoferrin seldom seems to result in cross immunisation against human lactoferrin, and the lack of correlation between levels of anti-human lactoferrin and anti-bovine lactoferrin shown in this study contradicts the hypothesis that cross immunisation against dietary bovine lactoferrin explains the appearance of anti-human lactoferrin autoantibodies. An exciting possibility is the antigen mimicry between the 65 kD mycobacterial heat-shock protein (hsp-65) and human lactoferrin, and the fact that immunisation against hsp-65 results in the production of anti-lactoferrin antibodies. Mycobacterial immunisation against mycobacterial antigens/hsp-65 have been implicated in several autoimmune disease states, both experimental and clinical. Considering the occurrence of IgA anti-lactoferrin antibodies in some cases of Crohn’s disease in the present study, we find it interesting that IgA (but not IgG) anti-hsp-65 antibodies have been reported in Crohn’s disease. Furthermore, the registration of anti-lactoferrin antibodies in a case of Campylobacter colitis in this study is interesting with regard to the possibility of cross immunisation against microbial antigen(s). We therefore intend to collect sera from patients with infectious gastroenteritis for the presence of anti-lactoferrin antibodies. In conclusion, we have shown high frequencies of IgG anti-lactoferrin antibodies in ulcerative colitis, and primary sclerosing cholangitis, but not in Crohn’s disease, whereas IgA autoantibodies directed against lactoferrin were found in some cases of both ulcerative colitis and Crohn’s disease. We suggest that anti-lactoferrin may be of pathogenetic significance by counteracting the antiphlogistic properties of lactoferrin at mucosal surfaces, thereby aggravating and/or sustaining mucosal inflammation initiated by other factors.

This study was financed by grants from Professor Nanna Sveriges Foundation, the Swedish Association against Rheumatism, King Gustaf Vh 80-Year Foundation, and the Swedish Medical Research Council.

10 Wiik A, Maunla E. Complement fixing granulocyte-specific antinuclear factors in neuropenic cases of rheumatoid arthritis. Immunology 1974; 26: 1127-34.


38 Kievits F, Kuijistra A. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin. _Immunology_ 1990; 70: 319-25.


Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease.

E Peen, S Almer, G Bodemar, B O Rydén, C Sjölin, K Tejle and T Skogh

Gut 1993 34: 56-62
doi: 10.1136/gut.34.1.56

Updated information and services can be found at:
http://gut.bmj.com/content/34/1/56

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Articles on similar topics can be found in the following collections

Pancreas and biliary tract (1949)
Crohn's disease (932)
Ulcerative colitis (1113)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/